BioSpace News Archive

Business

Money on the Move: Vita, scPharmaceuticals, Andera and More

This week, financing came in the form of loans, private placements and a Series B, throwing support behind an injectable heart failure drug, oral immunology therapies and an ASD treatment.

October 12, 2022
·
3 min read
·
Tristan Manalac
Business

Merck and Moderna Move Forward with Personalized Cancer Vaccine (Updated)

Merck and Moderna are moving forward with a personalized cancer vaccine as Merck exercised its option to develop and commercialize mRNA-4157/V940, the companies announced Wednesday.

October 12, 2022
·
3 min read
·
Mark Terry
Business

Terray and Calico Strike Biotech’s Latest R&D Deal Against Age-Related Diseases

Terray Therapeutics and Calico Life Sciences struck a research and development collaboration focused on the development of small-molecule therapeutics for age-related diseases.

October 12, 2022
·
3 min read
·
Alex Keown
Business

GreenLight Culls 25% of Staff in Pivot to Near-Term Commercial Programs

As part of a realignment, GreenLight Biosciences is cutting staff by about 25%, the company announced Wednesday.

October 12, 2022
·
2 min read
·
Mark Terry
Business

Eli Lilly Bets Nearly $500M on Metabolic Disease Pact with Nimbus (Updated)

Nimbus Therapeutics scored a $496 million payday through a collaboration and licensing deal with pharma giant Eli Lilly for potential therapeutics for metabolic diseases.

October 12, 2022
·
3 min read
·
Alex Keown
Business

Bayer’s Vividion Bets up to $930M for Tavros Oncology Partnership

Vividion Therapeutics and Tavros Therapeutics entered into a five-year collaboration agreement, valued at up to $930 million, to discover and develop four novel oncology targets.

October 12, 2022
·
2 min read
·
Tristan Manalac
Drug Development

Novartis’ Zolgensma Under Fire Again as Nature Retracts 2010 Paper

Novartis’ gene therapy Zolgensma is again under a cloud of doubt after Nature Biotechnology retracted its 2010 article noting “issues” regarding data cited in a key figure in the report.

October 12, 2022
·
3 min read
·
Alex Keown
World Muscle Society Congress 2022: Genentech, Fulcrum and Sarepta Present Latest Findings

The World Muscle Society 2022 Congress is ongoing in Halifax, Canada, with numerous companies presenting cutting-edge research in neuromuscular diseases. Here’s a look.

October 12, 2022
·
3 min read
·
Mark Terry
Business

Myth Busters: Dispelling Common Myths about Heart Disease, Diabetes and Alzheimer’s

The internet and “common wisdom” aren’t always right. Here are some of the top myths about three common conditions, and the truth from leading experts in their fields.

October 12, 2022
·
6 min read
·
Gail Dutton
Drug Development

Kronos Bio to Present Preclinical Data for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers, in Pediatric Cancer Models in Poster Presentation at EORTC-NCI-AACR 2022

Kronos Bio, Inc., a company dedicated to transforming the lives of those affected by cancer, announced that it will present preclinical data in a poster at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain.

October 12, 2022
·
4 min read